Literature DB >> 9468564

Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.

F Nomura1, A Koyama, M Ishijima, S Takano, M Narita, T Nakai.   

Abstract

The soluble cytokeratin 19 fragment (CYFRA) and pro-gastrin-releasing peptide (ProGRP) are recently described promising tumor markers for lung cancers. To assess their alterations in renal dysfunction, serum levels of CYFRA and ProGRP were determined together with conventional markers including carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), neuron specific enolase (NSE) in patients with renal failure of varying degrees. The mean concentration of all these markers but NSE significantly increased with the severity of renal failure. After hemodialysis (HD), the mean concentration of ProGRP, the molecular weight of which is comparable to that of 2-microglobulin, was significantly decreased. High false positive rates for tumor markers of lung cancer in patients with renal failure should be considered to avoid unnecessary diagnostic procedures.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468564     DOI: 10.3892/or.5.2.389

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  10 in total

Review 1.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

2.  False-positive findings for tumor markers after curative gastrectomy for gastric cancer.

Authors:  Takao Ohtsuka; Seiji Sato; Yoshihiko Kitajima; Masayuki Tanaka; Yuji Nakafusa; Kohji Miyazaki
Journal:  Dig Dis Sci       Date:  2007-05-03       Impact factor: 3.199

3.  Effect of renal function and hemodialysis on the serum tumor markers in patients with chronic kidney disease.

Authors:  Xiaofang Yu; Xialian Xu; Zhibin Ye
Journal:  Front Med China       Date:  2007-07

4.  Different roles of tumor marker monitoring after curative resections of gastric and colorectal cancers.

Authors:  Takao Ohtsuka; Yuji Nakafusa; Seiji Sato; Yoshihiko Kitajima; Masayuki Tanaka; Kohji Miyazaki
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

5.  Y-box protein-1/p18 fragment identifies malignancies in patients with chronic liver disease.

Authors:  Frank Tacke; Nicolas Kanig; Abdelaziz En-Nia; Thilo Kaehne; Christiane S Eberhardt; Victoria Shpacovitch; Christian Trautwein; Peter R Mertens
Journal:  BMC Cancer       Date:  2011-05-20       Impact factor: 4.430

6.  How to define a cut-off value of tumour markers in haemodialysis patients?

Authors:  Lucile Mercadal; Sylvie Cormont; Sophie Tezenas-du-Montcel; Sabria Hacini; Marcia Venditto; Gilbert Deray
Journal:  NDT Plus       Date:  2009-04

7.  Elevated Squamous Cell Carcinoma Antigen, Cytokeratin 19 Fragment, and Carcinoembryonic Antigen Levels in Diabetic Nephropathy.

Authors:  Jianzhong Chen; Feng Tao; Bin Zhang; Qingguang Chen; Yan Qiu; Qian Luo; Yanna Gen; Jiali Meng; Jue Zhang; Hao Lu
Journal:  Int J Endocrinol       Date:  2017-07-04       Impact factor: 3.257

8.  Relationship between Serum Level of Lymphatic Vessel Endothelial Hyaluronan Receptor-1 and Prognosis in Patients with Lung Cancer.

Authors:  Keiko Nunomiya; Yoko Shibata; Shuichi Abe; Sumito Inoue; Akira Igarashi; Keiko Yamauchi; Tomomi Kimura; Yasuko Aida; Takako Nemoto; Masamichi Sato; Hiroyuki Kishi; Hiroshi Nakano; Kento Sato; Isao Kubota
Journal:  J Cancer       Date:  2014-03-11       Impact factor: 4.207

9.  Reference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney disease.

Authors:  Gustav Mikkelsen; Arne Åsberg; Maria E Hultström; Knut Aasarød; Gunhild G Hov
Journal:  Int J Biol Markers       Date:  2017-10-31       Impact factor: 2.659

10.  Pro-gastrin-releasing peptide and outcome in patients with heart failure and anaemia: results from the RED-HF study.

Authors:  Thor Ueland; Lars Gullestad; Lei Kou; Pål Aukrust; Inderjit S Anand; Marianne Nordlund Broughton; John J McMurray; Dirk J van Veldhuisen; David J Warren; Nils Bolstad
Journal:  ESC Heart Fail       Date:  2018-08-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.